OCELLOS Pay-As-You-Go: TrakCel Delivers Rapid, Affordable Orchestration for Emerging Biotechs

OCELLOS Pay-As-You-Go: TrakCel Delivers Rapid, Affordable Orchestration for Emerging Biotechs

CARDIFF, Wales – Oct. 6, 2025 – TrakCel, a leading provider of integrated cell and gene therapy (CGT) orchestration solutions, today announced the launch of OCELLOS Pay-As-You-Go - a modular, Salesforce-powered portal now available as an off-the-shelf solution for advanced therapy management.

Emerging biotech companies often face financial constraints during early-stage clinical trials, leading to inefficient resource allocation and increased risk of costly delays or trial failure. To address this challenge, TrakCel has introduced OCELLOS Pay-As-You-Go - a flexible, cost-effective digital orchestration platform designed specifically for biotechs seeking to rapidly and affordably digitize their therapy workflows.

OCELLOS enables seamless integration across the advanced therapy supply chain, providing stakeholders with real-time access to critical information in a clear, actionable format. The portal supports compliance and standardization from day one, with pre-configured autologous workflows based on industry best practices - helping small teams reduce administrative burden and focus on patient outcomes.

Ravi Nalliah, CEO of TrakCel, said: “The cost of orchestration platforms can be a major barrier for early-stage biotechs. With OCELLOS Pay-As-You-Go, we’re removing that barrier - offering a low-risk, zero-deployment-fee solution that supports compliance and scalability from the outset.”

Key benefits of OCELLOS Pay-As-You-Go include:

• Rapid deployment: Ready to launch within one week, straight off the shelf.

• Flexible pricing: Sponsors only pay as patients are enrolled - no upfront costs, annual subscriptions, or minimum user commitments.

• Regulatory compliance: Suitable for both clinical and commercial use, with ICCBBA-compliant Chain of Identity (COI) tracking and automated audit trails.

• Real-time visibility: Secure, cloud-based access with time-stamped notifications to keep therapies on track.

•  

OCELLOS is already supporting over 3,700 users globally, with 1,600+ patients enrolled and 350+ site deployments worldwide - guiding therapies from clinical trial through to patient treatment.

ENDS

Media enquiries:

fiona.whyatt@ramarketingpr.com

About TrakCel

TrakCel is the market-leading developer of integrated cell orchestration solutions and services. TrakCel has specifically designed these solutions to manage the international autologous and allogeneic cell, gene, and immunotherapy value and supply chains. Its orchestration platform has evolved in collaboration with, and is increasingly adopted by, leading companies in the cell, gene, and immunotherapy industries. The service portfolio includes training, support, and consultancy offerings, all tailored to the unique needs of the CGT sector and drawing on TrakCel’s extensive experience in the industry.

TrakCel’s SaaS solutions enable real-time control for all organizations working across the entire therapeutic value chain. This control includes patient eligibility (commercial) and enrollment, sample collection, manufacturing, and treatment delivery. TrakCel aims to enable accelerated global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while safeguarding Chain of Custody (COC), Chain of Identity (COI), and audit trail for efficiency, compliance, and traceability. Founded in 2012, TrakCel is headquartered in Cardiff, UK, with offices in the US. For more information, visit www.trakcel.com.

www.trakcel.com